TGen Drug Development Services (TD2) will provide key drug development and regulatory services related to the clinical development of NeuVax, Apthera’s lead immunotherapy drug indicated for the adjuvant treatment of early-stage, lymph-node-positive breast cancer that contains the HER2 oncogene.
Apthera is currently preparing NeuVax for pivotal international Phase III clinical trials.
Alton Morgan, president and CEO of Apthera, said: “We feel that the extra capacity TD2 provides will help accelerate the development of our lead product, NeuVax, filling in vital, near-term responsibilities for our rapidly growing company.”